If you are wondering whether Travere Therapeutics at around US$27.82 still offers value, you are not alone, many investors are asking the same question as the stock has been on the radar of biotech ...

Executives from Travere Therapeutics (NASDAQ:TVTX) said the company is focused on advancing treatments in three rare diseases ...

Si-Bone (SIBN) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook gives a ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of the U.S. financial ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on February 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to ten new employees, ...

Travere Therapeutics is focused on rare kidney diseases, with FILSPARI driving significant revenue growth in IgA Nephropathy (IgAN). Competition in IgAN from larger players like Novartis and Vertex is ...

Travere Therapeutics, Inc. today announced that company management will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 4:00 p.m. ET. A live webcast ...

The purchase of Travere Therapeutics shares by Palisades Investment Partners is noteworthy because it represented a new position for the investment firm. The transaction came in the fourth quarter of ...

On the same dates, Dube exercised options to acquire 60,000 shares of Travere Therapeutics common stock at a price of $15.46, for a total value of $927600. In other recent news, Travere Therapeutics ...

BOSTON, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Travere Therapeutics, Inc. (Nasdaq: TVTX) for potential securities law violations. Investors who have lost money in their ...

Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best mid-cap growth stocks to buy right now. On January 14, Bank of America lowered its price target on Travere Therapeutics to $43 from $47, ...